Jie Xue

Jie Xue is an accomplished professional in the field of cancer immunotherapy with extensive experience in developing novel therapeutic biologics, including monoclonal antibodies for various cancer types. Currently serving as Director at Candid Therapeutics since October 2024, Jie Xue previously held the position of Senior Scientist and team leader at IGM Biosciences, Inc. from January 2023 to October 2024, and worked as a Senior Scientist at Binacea Pharma from June 2021 to January 2023. Prior experience includes project leadership roles at Hengenix Biotech, Inc., and research as a Postdoctoral Researcher at Stanford University, focusing on autoimmune diseases. Jie Xue earned a PhD in Biochemistry and Molecular Biology from the University of California, Merced, where previous research addressed strategies for HIV prevention, complemented by academic contributions as a Teaching Assistant. Education began with an undergraduate degree from Sun Yat-sen University.